Dose site reactions and related findings after vaccine administration in safety studies

被引:40
作者
Baldrick, Paul [1 ,2 ]
机构
[1] Lincoln Univ, Lincoln Sch Pharm, Lincoln, England
[2] Covance Labs Ltd, Regulatory Strategy, Harrogate, N Yorkshire, England
关键词
vaccine; adjuvant; toxicology testing; dose site; injection reactions; PRECLINICAL SAFETY; NONCLINICAL SAFETY; TOXICOLOGY; BIODISTRIBUTION; IMMUNOGENICITY; INJECTION; TOXICITY; SINGLE; RAT;
D O I
10.1002/jat.3314
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 [卫生毒理学];
摘要
Potential new human vaccines undergo toxicology testing to evaluate local reactogenicity and systemic toxicity. A review of 30 recently published and in-house repeat dose toxicity studies with a variety of vaccines was performed. Species tested were generally rat or rabbit, usually by intramuscular (although occasionally subcutaneous) injection. Results showed no unexpected findings indicating vaccine toxicity, but classic signs of enhanced acute and/or chronic inflammation at the dose site compared with that seen in injected control animals, often accompanied by changes in draining lymph nodes and the spleen (lymphoid hyperplasia and/or increased weight). Other associated signs of a response to vaccine dosing were altered clinical pathology parameters (commonly raised blood neutrophil count and altered globulin level). No obvious difference in dose site or systemic reaction was seen across vaccine, species or the dose route used. A non-dose recovery period of 2 to 4weeks was sufficient to show evidence of reversibility of dose site effects. Injection site, lymphoid tissue and clinical pathological changes can be interpreted as related to an expected reaction after vaccine dosing, with generation of an immune response largely as a result of the presence of adjuvant, although direct vaccine antigen involvement was also occasionally demonstrated by the presence of a slightly increased inflammatory response seen over adjuvant treatment only. Overall, the need for toxicity testing of vaccines is in line with current regulatory guideline requirements and has proven to be a valuable part of the safety evaluation process prior to human use. Copyright (c) 2016 John Wiley & Sons, Ltd. A review of 30 recently published and in-house repeat dose toxicity studies with a variety of vaccines was performed. Results indicated no unexpected findings indicating vaccine toxicity, but classic signs of enhanced acute and/or chronic inflammation at the dose site compared with that seen in injected control animals, often accompanied by changes in draining lymph nodes and the spleen (lymphoid hyperplasia and/or increased weight). Other associated signs of a response to vaccine dosing were altered clinical pathology parameters (commonly raised blood neutrophil count and altered globulin level).
引用
收藏
页码:980 / 990
页数:11
相关论文
共 33 条
[1]
[Anonymous], 2013, Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines
[2]
Bacardí Dania, 2013, Biotecnol Apl, V30, P118
[3]
Reproduction and juvenile animal toxicology studies in the rat with a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy [J].
Baldrick, Paul ;
Hewings, Simon ;
Skinner, Murray .
REPRODUCTIVE TOXICOLOGY, 2011, 32 (03) :322-328
[4]
Non-clinical safety evaluation of single and repeated intramuscular administrations of MAGE-A3 Cancer Immunotherapeutic in rabbits and cynomolgus monkeys [J].
Destexhe, Eric ;
Grosdidier, Emilie ;
Baudson, Nathalie ;
Forster, Roy ;
Gerard, Catherine ;
Garcon, Nathalie ;
Segal, Lawrence .
JOURNAL OF APPLIED TOXICOLOGY, 2015, 35 (07) :717-728
[5]
Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin® [J].
Doukas, John ;
Morrow, Jane ;
Bellinger, Dawn ;
Hilgert, Thomas ;
Martin, Terrie ;
Jones, Doug ;
Mahajan, Rohit ;
Rusalov, Denis ;
Sullivan, Sean ;
Rolland, Alain .
VACCINE, 2011, 29 (33) :5443-5452
[6]
EMA, 1998, EUR MED AG NOT GUID
[7]
Predictivity of animal studies for human injection site reactions with parenteral drug products [J].
Engelhardt, Jeffery A. .
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, 2008, 60 (4-5) :323-327
[8]
Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01 [J].
Fomsgaard, Anders ;
Karlsson, Ingrid ;
Gram, Gregers ;
Schou, Christian ;
Tang, Sheila ;
Bang, Peter ;
Kromann, Ingrid ;
Andersen, Peter ;
Andreasen, Lars Vibe .
VACCINE, 2011, 29 (40) :7067-7074
[9]
Garcon N, 2015, J APPL TOXICOL, V36, P238
[10]
The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm [J].
Ghimire, Tirth Raj .
SPRINGERPLUS, 2015, 4